Research programme: tyrosine kinase inhibitors - Cell Therapeutics
Alternative Names: c-kit oncogene inhibitors - Cell Therapeutics; Oncogenic pathway inhibitors - Cell TherapeuticsLatest Information Update: 09 Mar 2010
At a glance
- Originator Cell Therapeutics
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Sep 2005 This programme is still in active development
- 07 Jan 2004 Novuspharma has merged with and into Cell Therapeutics
- 09 Sep 2003 This programme is still in active development